Skip to main content
. 2019 Jun;31(3):481–488. doi: 10.21147/j.issn.1000-9604.2019.03.10

1.

1

Best clinical responses to crizotinib treatment in patients with evaluable lesions (n=368); the objective response rate (ORR) and disease control rate (DCR) for first-line vs. second-/later-line crizotinib were 74.1% vs. 69.9% (P=0.791) and 94.8% vs. 89.0% (P=0.038), respectively.